Lipum AB

We aim for an active lifestyle and improved quality of life for the millions affected by chronic inflammatory diseases.

[Lipum AB @lipumpharma]

https://t.co/jie82OYjna

[Lipum AB @lipumpharma]

Imorgon, 25 oktober kl 10:00, kommer VD Ola Sandborgh att kommentera kvartalsrapporten för juli-september 2024 i en webcast via Finwire. Se sändningen här: https://t.co/tGM6n5whJ7
Välkommen!

[Lipum AB @lipumpharma]

På fredag den 25 oktober bjuder G&W Fondkommission in Lipum till en presentation av kvartalsrapport och bolagets nuvarande status. Presentationen startar kl. 09:00. Registrera dig här: https://t.co/OWpQe2YPAo

[Lipum AB @lipumpharma]

- We are pleased with the successful collaboration with Karolinska Institutet. The research team’s work on BSSL is promising and could lead to more effective treatments for inflammatory diseases, says CEO Ola Sandborgh.
https://t.co/LHF874VcAt

[Lipum AB @lipumpharma]

Lipums vd Ola Sandborgh gästar Västra Hamnens studio och blir intervjuad av chefsanalytiker Martin Dominique om Lipums projekt, potential och planer.
https://t.co/d8WPrqj5Ic

[Lipum AB @lipumpharma]

Save the date: On November 4-6, Ola Sandborgh and Peter Hovstadius will participate at Bio-Europe 2024 in Stockholm. Welcome to meet them and learn more about Lipums first-in-class anti-BSSL antibody SOL-116 and the phase I study results.
Register here: https://t.co/XM8c0NQnvX

[Lipum AB @lipumpharma]

CEO Ola Sandborgh comments on article: "It is very gratifying that we have reached this point in the development program and will be able to receive a final report within a few months."
https://t.co/p4McjigCKI

[Lipum AB @lipumpharma]

"It is very satisfying that all healthy subjects and patients are now included in the phase 1 study," says Lipum's CEO Ola Sandborgh.
https://t.co/EN9oaadnU6

[Lipum AB @lipumpharma]

– It is important for me to work in an organisation that not only has great ideas but also the capacity to turn those ideas into reality, and always with the patient in mind, says Peter Hovstadius, Lipum´s new CMO.
https://t.co/nZNulM0Jsr

[Lipum AB @lipumpharma]

"Peter has valuable and extensive experience in the role of CMO as well as pharmacology and clinical trials. His strong drive and commitment will contribute to the success of our continued clinical development", says CEO Ola Sandborgh.
https://t.co/KdxQPI7aZI

[Lipum AB @lipumpharma]

Ola Sandborgh summarizes his first six months as Lipum's new CEO: "Intense, enjoyable, and progress in the project that makes me very satisfied and proud!"
#lipum #biostock #sol_116 #lifescience
https://t.co/11yNW2XOmh

[Lipum AB @lipumpharma]

”Jag är mycket glad över att leda Lipums verksamhet och känner en stor tillfredsställelse över vad som uträttades under förra året”, säger Lipums VD Ola Sandborgh.
#lipum #arsredovisning #fas_1 #fas_2 #lifescience
https://t.co/z9ndOypTDh

[Lipum AB @lipumpharma]

– I would like to extend a big thank you to everyone who participated in the rights issue. Our successful development can continue according to plan, says CEO Ola Sandborgh. Read the article from @BioStock_News here.
https://t.co/o2btkKL5kk

[Lipum AB @lipumpharma]

At the moment, CEO Ola Sandborgh is at LSX - partnering for Life Science eXecutives congress. Take the opportunity to book a meeting and learn about Lipum's future development.

[Lipum AB @lipumpharma]

"We are delighted to be partnering with NorthX and it represents an important step as we move forward into our phase II trial", says CEO Ola Sandborgh.
https://t.co/f4kxDqxfxU

[Lipum AB @lipumpharma]

On April 29-30, Lipum's CEO, Ola Sandborgh, will participate in the LSX World Congress to attend investor meetings and present Lipum's ongoing development.

[Lipum AB @lipumpharma]

Lipum genomför en företrädesemission för att finansiera utvecklingen av SOL-116, med möjlighet att tillföra 187,2 Mkr vid full teckning, främst för att slutföra den pågående kliniska fas I-studien. Läs artikeln från @BioStock_SWE här.
https://t.co/FiTYabuYoA

[Lipum AB @lipumpharma]

Lipum has been been granted 2,8 MSEK from Swelife. The project is a collaboration between Lipum, Karolinska Institutet, Stockholms stad and Linköpings universitet.
https://t.co/6f1NXmFJQc

[Lipum AB @lipumpharma]

9 april startade teckningsperioden i Lipums företrädesemission. Kapitaltillskottet ska användas för att ta läkemedelskandidaten SOL-116 till kliniska fas II-studier, med målet att visa effekt på patienter med ledgångsreumatism.
https://t.co/GfULv3adyt

[Lipum AB @lipumpharma]

To enable future exploitation of SOL-116 for the treatment of cancer, Lipum has applied for intellectual property protection and this international patent application will become public on 14 April 2024.
https://t.co/wxQDo1Uymd